skip menus and go right to content

 SEARCH

 LifeWatch

LifeWatch Employee Assistance Program
1-800-333-6228
Or
TTT/TTY
1-800-745-5555


 RESOURCES


 MORE


 

HOME · TOPICS · NEWS · READING · ABOUT · HELP
 
 
Alzheimers And Other Dementias - Alzheimer's Disease Medications
Topic Home · Related:  
Alzheimer's Disease Medications
ADEAR

[Editor's Note: This document was last updated in May, 2002 and is now slightly out of date. The FDA has recently approved a new medication, Namenda® (memantine HCl), an NMDA receptor antagonist for the treatment of moderate to severe Alzheimer's disease. This medicine is expected to be available in USA pharmacies in January 2004. More information on Namenda and related medicines is forthcoming.]


Four prescription drugs currently are approved by the U.S. Food and Drug Administration to treat the symptoms of mild to moderate Alzheimer’s disease (AD). These medications are called "cholinesterase inhibitors." Scientists do not yet fully understand how these medications work to treat AD, but current research suggests that each acts to prevent the breakdown of acetylcholine, a brain chemical believed to be important for memory and thinking. These medications can help delay or prevent symptoms from becoming worse for a limited time and may help control some behavioral symptoms. Treating the symptoms of AD can provide patients with comfort, dignity, and independence for a longer period of time and can encourage and assist their caregivers as well.

None of these medications stops the disease itself. As AD progresses, the brain produces less and less acetylcholine, and the medications may eventually lose their effect. No published study directly compares these drugs. Because all four work in a similar way, it is not expected that switching from one of these drugs to another will produce significantly different results. However, an AD patient may respond better to one drug than another.

Some additional differences among these medications are summarized in the table on the other side. The medications (listed from most recent to last as approved by the FDA) are:

  • Reminyl®
  • Exelon®
  • Aricept®
  • Cognex® (Note: Cognex is still available but is not actively marketed by the manufacturer.)

Benefits reported for these medications tend to occur at higher doses. However, the higher the dose, the more likely are side effects. Doctors usually start patients at low doses, and gradually increase the dosage based on how well a patient tolerates the drug. Patients may be drug-sensitive in other ways, and they should be monitored for unusual symptoms when a drug is started. Report any unusual symptoms to the prescribing doctor right away.

It is important to follow the doctor’s instructions when taking any medication, including vitamins and herbal supplements. Also, let the doctor know before adding or changing any medications.

Table - Medications Summary

Note: The brief summary provided below does not include all information important for patient use and should not be used as a substitute for professional medical advice. Consult the prescribing doctor and read the package insert before using these or any other medications or supplements. Drugs are listed from most recent to last, as approved by the FDA.
DRUG NAMERECOMMENDED DOSAGECOMMON SIDE EFFECTSPOSSIBLE DRUG INTERACTIONS
Reminyl® (galantamine) Prevents the breakdown of acetylcholine and stimulates nicotinic receptors to release more acetylcholine in the brain.
  • 4mg, twice a day (8mg/day)
  • Increase by 8mg/day after 4 weeks to 8mg, twice a day (16mg/day).
  • After another 4 weeks, increase to 12mg, twice a day (24mg/day), if well tolerated.
Nausea, vomiting, diarrhea, weight loss Some antidepressants such as paroxetine, amitriptyline, fluoxetine, fluvoxamine, and other drugs with anticholinergic action may cause retention of excess Reminyl in the body, leading to complications; NSAIDs should be used with caution in combination with this medication.*
Exelon® (rivastigmine) Prevents the breakdown of acetylcholine and butyrylcholine (a brain chemical similar to acetylcholine) in the brain.
  • 1.5mg, twice a day (3mg/day)
  • Increase by 3mg/day every 2 weeks to 6mg, twice a day (12mg/day).
  • Continue up to 6mg, twice a day (12mg/day), if well tolerated.
Nausea, vomiting, weight loss, upset stomach, muscle weakness None observed in laboratory studies, NSAIDs should be used with caution in combination with this medication.*
Aricept® (donepezil) Prevents the breakdown of acetylcholine in the brain.
  • 5mg, once a day
  • Increase after 4-6 weeks to 10mg, once a day.
Nausea, diarrhea, vomiting None observed in laboratory studies, but NSAIDs should be used with caution in combination with this medication.*
Cognex® (tacrine) Prevents the breakdown of acetylcholine in the body, not specific to the brain. Note: Cognex is still available but no longer actively marketed by the manufacturer.
  • 10mg, four times a day (40mg/day)
  • Increase by 40mg/day every 4 weeks to 40mg, four times a day (160mg/day), if liver enzyme functions remain normal.
Nausea, diarrhea, possible liver damage NSAIDs should be used with caution in combination with this medication.*

* Use of cholinesterase inhibitors can increase risk of stomach ulcers, and because prolonged use of non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin or ibuprofen can also cause stomach ulcers, NSAIDS should be used with caution in combination with these medications.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
National Institutes of Health
National Institute on Aging
Published in May 2002

This document sourced from the Alzheimer's Disease Education and Referral Center, a service of the National Institute on Aging.

 

 BASIC INFORMATION

 DETAILED INFORMATION

 NEWS

 LINKS

 BOOK REVIEWS